跳至主要内容
临床试验/NCT04488718
NCT04488718Unknown不适用

Evaluation of Tolerance and Acceptability of EnergieShake® Junior Powder Complete

Anaiah Healthcare Pvt Ltd3 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2020年9月24日最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
入组人数
18
试验地点
3
主要终点
Acceptability & Tolerance: questionnaire

研究概览

简要总结

The goal of this study is to gather data on the tolerance and acceptability of a new ONS (ESj-powder complete) in children currently taking ONS.

详细描述

The goal of this study is to demonstrate the tolerance and acceptability of the test product when consumed by children who are currently prescribed (a similar) ONS. The data generated from this study will be submitted to the ACBS, who will consider it for reimbursement as a Food for Special Medical Purpose (FSMP) in the UK.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
1 Year 至 18 Years(Child, Adult)
性别
All
接受健康志愿者
否

入选标准

  • •>1-18 years of age
  • •Children currently prescribed and consuming Oral Nutritional Supplements (ONS)
  • •Willingness to take part in the study, and consent to the study protocol signed by parent/guardian or older child (when appropriate)

排除标准

  • •Participants requiring exclusive enteral tube feeding
  • •Participants on parenteral nutrition
  • •Participants with cow's milk or soy allergy or lactose intolerance
  • •Participants with galactosaemia
  • •Participants with a chronic renal or liver disease
  • •Participants who are acutely unwell

研究组 & 干预措施

EnergieShake® Junior Powder Complete (test)

Experimental

EnergieShake® Junior Powder Complete will be consumed by children, as a supplement to normal diet, over a period of 7 day period to determine its acceptability (liking, compliance) and tolerance (gastro-intestinal tolerance). The dose will be the same as currently consumed product (all children recruited to the study will be consuming an oral nutritional supplement).

干预措施: EnergieShake® Junior Powder Complete (Other)

结局指标

主要结局

Acceptability & Tolerance: questionnaire

时间窗: 7 days

Acceptability of test product will be tested in children using a questionnaire with a liking scale (Liking Scale - 1-10 - 0 being dislike and 10 being like a lot) and compliance (intake/day versus prescribed dose) of the test product over a 7 day period and compared to acceptability when consuming their current oral nutritional supplement

Gastrointestinal Tolerance

时间窗: 7 days

Gastrointestinal (GI) tolerance of test product will be determined in children using a questionnaire detailing daily bowel habits and symptoms that occur (new or worsening) while consuming the test product over a 7 day period and compared to GI tolerance when consuming their current oral nutritional supplement. This is established using a combination of the Bristol Stool Chart scoring (BSC - type 1 up to type 7) before and during the study along with number of bowel movements/day and stool consistency.

次要结局

未报告次要终点

研究者

发起方
Anaiah Healthcare Pvt Ltd
申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验

招募中
1 期
ONO-7475-04:A Phase1 study of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and ONO-7475 in combination with GnP in patients with pancreatic cancermetastatic pancreatic cancer
JPRN-jRCT2031230429Hirashima Yoshinori87
已完成
1 期
A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme PatientsGlioblastoma Multiforme
NCT01588769CytoVac A/S23
进行中(未招募)
1 期
A Phase III Study to Assess the Tolerability and Efficacy of MK-0822 (Odanacatib) in Reducing the Risk of Bone Metastases and Prolonging Disease-Free Survival in Women with Breast Cancer Spanish title: Estudio de Fase III para evaluar la tolerabilidad y eficacia de MK-0822 (Odanacatib) en la reducción del riesgo de desarrollar metástasis óseas y en la prolongación de la supervivencia libre de progresión en mujeres con cáncer de mama” - MK-0822 (Odanacatib) in Women with Breast CancerPrevention of disease recurrence in patients with breast cancer. Spanish indication: Prevención de recurrencia de la enfermedad en pacientes con cáncer de mamaMedDRA version: 9.1 Level: LLT Classification code 10005993 Term: Bone metastases
EUCTR2008-002119-42-ESMerck& Co., Inc.4,000
进行中(未招募)
1 期
A Phase III Study to Assess the Tolerability and Efficacy of MK-0822 (Odanacatib) in Reducing the Risk of Bone Metastases and Prolonging Disease-Free Survival in Women with Breast Cancer - MK-0822 (Odanacatib) in Women with Breast CancerPrevention of disease recurrence in patients with breast cancer.MedDRA version: 9.1Level: LLTClassification code 10005993Term: Bone metastases
EUCTR2008-002119-42-SKMerck& Co., Inc.4,000
撤回
不适用
GI Tolerance and Acceptability of a New ThickenerGastro-intestinal Tolerance
NCT04104815Abbott Nutrition